SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis

A new analysis of the SPARCL trial has shown that the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news